Pangaea Data is Attending the JPM Healthcare Conference

JAMIA Publication:The Potential and Pitfalls of using a LLM as a Clinical Assistant

Full Steam Ahead: How AI Can Transform the Genetics Journey in Precision Medicine

Pangaea Data Selected for NVIDIA & Microsoft’s New AI Initiative

From Thin Ice to Solid Ground: How AI is Changing Clinical Practice for the Better

GO BACK

Pangaea Named ‘Digital Solution of the Year’ by UK Government’s Department for International Trade

British embassies around the globe will be showcasing Pangaea’s AI-driven product platform throughout the year

South San Francisco, USA, 31 January 2023: Pangaea Data, (Pangaea), provider of a novel AI-driven product for characterizing patients by mapping their journeys and disease trajectories in a privacy-preserving and scalable manner, today announced that it has been named “Digital Solution of the Year” by the UK Government’s Department for International Trade, as part of its 2023 UK Life Science Innovator Showcase. UK DIT selected Pangaea for this award from thousands of UK companies across the life science industry as a direct result of its international growth and innovative approach to tackling healthcare challenges.

This award follows Pangaea’s selection by the UK DIT as a Leading Digital Health Innovator, and inclusion in the UK government’s Digital Health Playbook for the second consecutive year. The UK Digital Health Playbook showcases the top UK innovators and exporters, providing solutions for current challenges in digital health, including scaling the power of AI for improved diagnoses and more accurate predictions.1

Pangaea’s AI-driven product, Pangaea’s Intelligence Extraction and Summarization (PIES), characterizes patients by mapping their journeys and disease trajectories in an evolving, federated privacy-preserving and scalable manner, which is critical for preventative health and precision medicine. This is achieved by PIES unlocking and summarizing clinically actionable intelligence from patient records without touching or moving them, which has proven to find 22 times more undiagnosed, miscoded and at-risk patients; match patients to five times more suitable clinical trials and therapies; discover new relationships between drugs, features and adverse events; predict prognosis; halve treatment costs; and save 90% in costs and time compared to manual and alternative natural language processing (NLP)-based methods. 

Dr Vibhor Gupta, CEO and Founder of Pangaea, said:We are proud to have been selected by DIT for this award, which highlights the value we have created for both patients and clinicians through our novel AI-driven product, which will be critical in realizing the promise of preventative health and precision medicine across the healthcare and pharmaceutical industry. This is also a testament to our proven track-record of success and collaboration, as well as our continued commitment to international expansion.”

Dr Neil Ebenezer, Medical Technology and Genomics Specialist, Department for International Trade, said:DIT are really pleased to announce the launch of our 2023 UK Life Science Innovator Showcase. These UK companies are at the forefront of life sciences innovation, with solutions that look to deliver on a global scale. DIT are pleased to announce Pangaea as the category winner for Digital Solutions. Pangaea uses existing patient data to provide deeper insights that may allow healthcare professionals to improve patient treatment pathways. We were impressed with their novel AI-driven product that has a proven track record in improving healthcare outcomes.

References: [1] The UK’s Digital Health Playbook 2023 Edition

Email: pr@pangaeadata.ai

About Pangaea:

Pangaea Data is a South San Francisco and London based provider of a novel AI-driven product for characterizing patients by mapping their journeys and disease trajectories in an evolving, privacy-preserving and scalable manner, which has clinically proven to discover 22x more undiagnosed, misdiagnosed and miscoded patients; match 5x more suitable clinical trials to patients; discover new insights across rare and hard-to-diagnose conditions; halve treatment costs; save 90% in operational costs and time; and drive sustainable collaborations between the healthcare and the pharmaceutical industry. The founders (Dr. Vibhor Gupta and Prof. Yike Guo) have attracted more than $200 million through their research and the company is advised by Lord David Prior (former Chairman of NHS England and Vice Chairman of Lazards), Mr. Andy Palmer (former Head of Systems Integration at Novartis and a prolific serial entrepreneur) and has published its work in high-impact, peer-reviewed journals and at conferences.